Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YH012
- Development stage
- Unknown
- Lead developer
- Biocytogen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
YH012 is a first-in-class bispecific antibody-drug conjugate (BsADC) that targets both Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (TROP2). Developed by Biocytogen (and its subsidiary Eucure Biopharma), YH012 consists of a fully human bispecific antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. The drug is designed to treat a variety of solid tumors, including those with low HER2 expression, by leveraging the co-expression of TROP2 to enhance tumor-specific targeting and internalization. Preclinical data presented at AACR 2023 demonstrated superior anti-tumor efficacy compared to parental monoclonal antibodies in models of gastric, colorectal, breast, and non-small cell lung cancer (NSCLC). The dual-targeting approach aims to increase tissue specificity and selectivity while reducing potential toxicity.
- Brand names
- RB-201RB201RB 201
- Other names
- anti-HER2/TROP2 BsADC
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TACSTD2 (Tumor-associated calcium signal transducer 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on YH012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YH012.